CAPTRUST Financial Advisors
VOR icon

CAPTRUST Financial Advisors’s Vor Biopharma VOR Stock Holding History

CAPTRUST Financial Advisors’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed -$1K – 4928
2021
Q3 		$1K Buy
+2
New +$595 ﹤0.01% 4500

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

CAPTRUST Financial Advisors's VOR Position: Q4 2021 in Review

CAPTRUST Financial Advisors sold out of Vor Biopharma (VOR) in Q4 2021, closing a stake of 2 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in VOR in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 61 funds tracked by Wall St. Rank hold VOR as of Q4 2021.

  • CAPTRUST Financial Advisors reported no remaining Vor Biopharma position as of Q4 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 2 Vor Biopharma shares in Q4 2021, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Vor Biopharma in Q3 2021 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Vor Biopharma position peaked at $1K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.